IN THIS ISSUE

The pharma industry has not had a smooth ride over the past 12 months, as high-profile drug scandals, medication shortages and debates over drug prices have dominated headlines, and thrown a wrench into the future plans of industry leaders.


In this special yearbook issue of Pharma Technology Focus, we take a look back at the biggest stories from 2019, from unlocking gut-based drug discovery to the costly impact of the Valsartan recall.


Also, we investigate the disappearance of pink Migraleve in the UK, discuss drug reform policy with psychedelics campaigner Amanda Feilding, and chart the EMA’s time in London now that the organisation has relocated to the Netherlands.


Plus, we sort through the myths and mysteries surrounding CBD, debate the case for and against a nationalised drug company in the UK, and find out more about how cancer cells communicate.


And finally, we investigate the rise of buyers clubs as patients fight to access lifesaving medication, ask if we are nearing the end of animal testing, and take a look at the latest innovation in targeted cancer treatment.


Eloise McLennan, editor

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue